Saturday 17 October 2026
Export GELS’s income statement to Excel — free account
Gelteq Limited
GELS Healthcare Drug Manufacturers Specialty & Generic
Gelteq Limited’s revenue for fiscal 2025 (year ended June 2025) was $368,500.00, up 282.7% from fiscal 2024.
0.45
0.02
+4.65%
Follow GELS
| Dec '25 | Jun '25 | Dec '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | — | — |
+2 more TTM periods Free account |
|
| 0.00% | 0.00% | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow |
(6.83) | (6.63) | (4.26) | — | |
Capital Expenditures |
— | (0.01) | (0.03) | — | |
| Other line items | |||||
Cash ROIC |
(53.81%) | (50.24%) | (25.43%) | 0.00% | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
0.00 | — | 0.00 | — | |
Capex/Depreciation |
— | 0.00 | 0.00 | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | — | |
Capex per Share |
— | 0.00 | 0.00 | — | |
Capex to Sales |
— | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 5 Oct 2026